01—Abstract
Summary
Summary of the 10-Q filed October 29, 2002. Cited figures are marked; the original filing is the authoritative source.
CME Group Inc. (CME) reported strong financial performance for the nine months ending September 30, 2002, driven by a significant increase in trading volume.
Net income rose to $61.0 milliona from $54.5 million in the prior year period, with net revenues increasing by 18.3%. This growth was primarily fueled by a 39.3% surge in average daily trading volume, particularly in interest rate and equity products, and a substantial increase in electronic trading on the GLOBEX platform. The company experienced a notable increase in total assets, largely due to a significant rise in cash performance bonds and security deposits held, alongside a substantial increase in cash and cash equivalents.
While expenses also grew, largely due to a one-time patent litigation settlement charge of $13.7 millionb, the overall revenue growth outpaced expense increases. CME Group also announced its intention to initiate regular quarterly dividends starting in Q1 2003, signaling confidence in its financial health and future cash flows.
02—Key points
Key Highlights
- Net income increased to $61.0 million for the nine months ended September 30, 2002, up from $54.5 million in the same period of 2001.
- Net revenues grew by 18.3% to $333.8 million for the nine months ended September 30, 2002, driven by an 18.3% increase in clearing and transaction fees.
- Total trading volume increased by 39.3% to 413.8 million contracts for the nine months ended September 30, 2002, with electronic trading volume on GLOBEX showing a significant 133.9% increase.
- Cash and cash equivalents nearly tripled, reaching $197.2 million at September 30, 2002, compared to $69.1 million at December 31, 2001, primarily due to a change in investment policy.
- Total assets saw a significant increase, driven by a rise in cash performance bonds and security deposits, and a substantial growth in cash and cash equivalents.
- A one-time patent litigation settlement expense of $13.7 million was recorded in the third quarter of 2002.
- The company plans to initiate regular quarterly dividends beginning in the first quarter of 2003.
03—Questions
Frequently Asked Questions
What drove the increase in CME's revenues for the nine months ended September 30, 2002?
CME's revenues were primarily driven by a significant increase in trading volume, which grew by 39.3%. This surge was particularly notable in interest rate and equity products, and was complemented by a substantial 133.9% increase in electronic trading volume on the GLOBEX platform. Clearing and transaction fees, the company's largest revenue source, increased by 23.3% as a result.
How did the Wagner patent litigation settlement impact the financial results?
The company recorded a one-time expense of $13.7 million in the third quarter of 2002 related to the settlement of the Wagner patent litigation. This settlement involved an initial payment in September 2002 and five subsequent annual payments. This expense had a notable impact on the expenses for the period.
What is the current liquidity position of CME Group?
CME Group's liquidity has significantly improved. Cash and cash equivalents increased substantially from $69.1 million at December 31, 2001, to $197.2 million at September 30, 2002. This growth was largely attributed to a change in investment policy that converted marketable securities into short-term investments treated as cash equivalents, alongside strong operating cash flows.
Are there any new developments regarding shareholder returns?
Yes, CME Group announced its intention to pay regular quarterly dividends to shareholders beginning in the first quarter of 2003, targeting approximately 20% of the prior year's cash earnings. This indicates a positive outlook on future profitability and cash generation.
04—Continue